These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15704575)

  • 21. Alendronate treatment for osteoporosis.
    Brager R
    Adv Nurse Pract; 1997 Mar; 5(3):28-34. PubMed ID: 9459879
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
    Ozdemir F; Rodoplu M
    Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spine studies to remain part of bone analysis.
    Diagn Imaging (San Franc); 1998 Nov; Suppl Bone Mass():6. PubMed ID: 10345144
    [No Abstract]   [Full Text] [Related]  

  • 25. [Osteoporosis medications. Bisphosphonates exceed the others].
    MMW Fortschr Med; 2003 Oct; 145(42):66. PubMed ID: 14655453
    [No Abstract]   [Full Text] [Related]  

  • 26. [Alendronate once a week].
    Brixen KT; Mosekilde L
    Ugeskr Laeger; 2003 Jun; 165(27):2734-9. PubMed ID: 12886563
    [No Abstract]   [Full Text] [Related]  

  • 27. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 28. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. By the way, doctor. I'm 69 and have taking Fosamax for 10 years. My doctor has approved a "drug holiday," provided we use a CTX test to monitor my bones. Can you explain?
    Robb-Nicholson C
    Harv Womens Health Watch; 2009 May; 16(9):8. PubMed ID: 19554747
    [No Abstract]   [Full Text] [Related]  

  • 30. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of osteoporosis. Compliance is significantly enhanced].
    Meissner T
    MMW Fortschr Med; 2001 May; 143(22):53. PubMed ID: 11460408
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term use of Fosamax sustains or continues increases in bone density.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Apr; 15(8):9-10, 12. PubMed ID: 15112661
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 35. By the way, doctor. I recently heard that I can take Fosamax once a week for osteoporosis, rather than every day. Is it really effective when taken this way? Is there a downside?
    Robb-Nicholson C
    Harv Womens Health Watch; 2001 May; 8(9):8. PubMed ID: 11410457
    [No Abstract]   [Full Text] [Related]  

  • 36. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [FOSAVANCE -- alendronate plus vitamin D in a weekly tablet].
    Praxis (Bern 1994); 2006 Jul; 95(27-28):2 p following 1084. PubMed ID: 16888927
    [No Abstract]   [Full Text] [Related]  

  • 39. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P; Stancíková M; Letkovská A; Rovenský J
    Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.